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Context: There are interplays between the endocrine and exocrine pancreas.We recently reported
an increased frequency of exocrine dysfunction in HNF1A-maturity-onset diabetes of the young
(MODY3) patients, compared with controls. Reduced pancreatic volume is seen in HNF1B-MODY
(MODY5) and diabetes types 1 and 2.
Objective: The aimof this studywas to investigatewhetherHNF1Amutation carriers have reduced
pancreatic volume or abnormal pancreatic structure andwhether any changes are associatedwith
exocrine dysfunction.
Methods: Fifteen HNF1A mutation carriers recruited from the Norwegian MODY Registry, 31
subjects with type 1 diabetes, 10 subjects with type 2 diabetes, and 11 controls underwent com-
puted tomography of the pancreas. We measured pancreatic volume and X-ray attenuation. Pan-
creatic volume index was defined as pancreatic volume divided by body surface area.
Results: Pancreatic volume indexwas reduced in subjectswithHNF1A-MODY (34.5ml/m2; P 0.02)
and type 1 diabetes (21.4 ml/m2; P  0.001) as compared with nondiabetic controls (45.7 ml/m2),
andwas reduced in subjects with diabetes in combinationwith fecal elastase deficiency (P 0.03).
Subjects with type 1 diabetes had smaller pancreatic volume index, compared with HNF1A muta-
tion carriers (P 0.001). Reducedpancreatic volume indexwas associatedwith increasingduration
of diabetes. Pancreatic X-ray attenuation in HNF1A mutation carriers was not significantly differ-
ent from that of nondiabetic controls.
Conclusions: HNF1A mutation carriers have reduced pancreatic volume but less reduced than in
patients with type 1 diabetes. Insulinopenia could explain both the pancreatic volume reduction
and the associated pancreatic dysfunction. (J Clin Endocrinol Metab 93: 3505–3509, 2008)
There is an exocrine component in several formsofmonogenicdiabetes. Inmaturity-onset diabetes of the young (MODY)
due to mutations in HNF1B (HNF1B-MODY, MODY5), pan-
creatic atrophy is a common feature (1, 2) andmost likely caused
by a developmental defect (3). Moreover, we have described
pancreatic atrophy and lipomatosis in subjectswith diabetes and
pancreatic exocrine dysfunction caused by mutations in the car-
boxyl-ester lipase (CEL) gene (4, 5), suggesting that fatty re-
placement could reflect a process involved in pancreatic disease
development in this MODY subtype. Interestingly, radiological
studies have reported reduced pancreatic volume in patients
with type 1 diabetes and to some degree in patients with insulin-
dependent type 2 diabetes (6–8). The pancreatic size reduction in
type 1 and 2 diabetesmay be secondary to a reduced insulinotropic
effect on the acinar cells (9–11). A correlation between the pancre-
atic volume and pancreatic exocrine function measured by serum
immunoreactive trypsin has also been reported (6).
We recently found that 13% of adult HNF1A mutation
carriers have pancreatic exocrine dysfunction (12). HNF1A is
closely related toHNF1B. Hence,morphological changes sim-
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ilar to those reported for HNF1B-MODY might be suspected.
We therefore aimed to study pancreatic structure and its re-
lation to exocrine function in HNF1A-MODY and to make a
comparison with type 1 and type 2 diabetes subjects as well as
normal controls.
Subjects and Methods
Subjects
We invited all adult HNF1A mutation carriers in the Norwegian
MODY Registry and subjects with types 1 and 2 diabetes recruited con-
secutively from an outpatient diabetes clinic to test for pancreatic exo-
crine dysfunction. The clinical characteristics of the study subjects are
described inTable 1. Subjects diagnosedwith exocrine dysfunction,were
compared with subjects of the same diabetes subtype but with normal
exocrine function. There was no significant difference in age, age at
examination, body mass index (BMI) or body surface area between the
groups. All subjects were investigated with computed tomography (CT)
of the pancreas by a standardized protocol. From a CT archive, we
included controls without known diabetes or pancreatic disease that
were matched for age, sex, and body surface area.
The study was approved by the Regional Committee for Research
Ethics and theNorwegianData Inspectorate andperformedaccording to
theHelsinkiDeclaration.Weobtainedwritten informed consent fromall
participants.
Measurement of pancreatic volume and x-ray
attenuation
For the radiological study, helical CT (Light Speed Ultra; GE,
Milwaukee,WI)of thepancreas (5mmcollimation, 5mmreconstruction
increment) was performed with and without contrast. Some examina-
tions performed at local hospitals had slightlymodified scan parameters.
A radiologist (I.S.H.) traced the contourof thepancreasoncontrast series
on every slice to estimate the pancreatic volume as previously described
(4) Pancreatic attenuation on contrast series in the encircled areas were
used to calculate averagex-rayattenuationmeasured inHounsfieldUnits
(HU; values equaling1000 in air,100 in fat, 0 in water, and1000
inbone).Tocontrol for the influenceofbodybuildonpancreatic volume,
the pancreatic volume index was calculated by dividing pancreatic vol-
umebybody surface area (6) as calculated by the formula ofDuBois (13).
Definition of pancreatic exocrine dysfunction
Fecal elastase-1was determinedbyELISAusing akit specific for human
elastase-1 (ScheBo-Tech GmbH, Wettenberg-Giessen, Germany). Pancre-
atic exocrine dysfunction was defined as fecal elastase deficiency, i.e.
fecal elastase levels less than 200 g/g in two consecutive tests. Seventy-
two-hour stool samples were collected as previously described (12),and
fecal fatwasquantified according tovandeKamer et al. (14), considering
7 g or less of fat per 24 h normal.
Statistics
Results for continuous variables are given as mean (SD). We used
one-way ANOVA for global assessment and two-tailed, unpaired Stu-
dent’s t tests in the subgroup analyses for comparison of clinical char-
acteristics and for comparison of pancreatic volume index and x-ray
attenuation between HNF1A mutation carriers and each control group.
We chose a significance level of 5%but 1%in the case ofmultiple testing.
Associations between pancreatic volume index and attenuation, respec-
tively, with age, BMI, duration of diabetes, fecal elastase level (contin-
uous), and fecal elastase deficiency status (defined as a discrete variable:
fecal elastase more or less than 200 g/g), respectively, were computed
byunivariate ormultivariate linear regression (supplementarydata, pub-
lished as supplemental data on The Endocrine Society’s Journals Online
Web site at http://jcem.endojournals.org). In the multiple regression
analyses, age and the significant variables from the univariate analyses
were included. All data were analyzed using Stata 8.0 (Stata Statistical
Software, Stata Corp., College Station, TX).
Results
By CT, none of the patients with exocrine dysfunction displayed
dilatation of the pancreatic duct, calcifications, or pseudocysts,
which are frequently identified in chronic pancreatitis. Clinical
characteristics are given in Table 1.
Pancreatic volume
The global assessment by ANOVA showed significant vari-
ance for the pancreatic volume index (P  0.00001; F 18.98,
3 df). Mean pancreatic volume index was reduced in HNF1A
mutation carriers (34.5 ml/m2  9.9) as well as type 1 diabetes
patients (21.4 ml/m2  7.4), compared with nondiabetic con-
trols (45.7 ml/m2 11.8; P 0.007 and 0.001, respectively),
whereas for type 2 diabetes patients, no significant reduction in
pancreatic volume index was seen (36.9 ml/m2 13.2; Fig. 1A).
Type 1 diabetes subjects had smaller pancreatic volume index,
compared with HNF1A mutation carriers (P 0.001). Further-
TABLE 1. Characteristics of the study subjects
MODY3
Nondiabetic
controls P1
Type 1
diabetes P2
Type 2
diabetes P3
n 15 11 31 10
Males, n (%) 7 (47) 7 (64) 24 (77) 8 (80)
Age at examination (yr) 51  13 51  10 ns 52  12 ns 60  11 ns
Age at onset of diabetes (yr) 24  9 NA 22  13 ns 48  10 0.001
Duration of diabetes (yr) 28  13 NA 31  15 ns 12  6 0.001
BMI (kg/m2) 25  3 26  4 ns 26  3 ns 27  2 ns
Body surface area (m2) 1.9  0.1 1.9  0.3 ns 2.0  0.2 ns 2.0  0.1 ns
Fecal elastase deficiency, n (%) 5 (33) NI 15 (48) 5 (50)
Fecal fat excretion (g/d) (7)a 14  7 NI 12  5 ns 9  6 ns
Fecal fat excretion greater than 7 g/d, n 6 of 6 NI 14 of 17 1 of 3
Data are means  SD. The P values represent two-sample Student’s t tests comparing MODY3 and P1 (nondiabetic controls), P2 (type 1 diabetes subjects), and P3 (type
2 diabetes subjects), respectively. NA, Not applicable; NI, not investigated; ns, not significant.
a Fecal fat excretion was measured in six MODY3, 17 type 1 diabetes, and three type 2 diabetes subjects.
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more, diabetes durationwas inversely associatedwithpancreatic
volume index in all diabetes patients [P  0.001,   0.37
(0.58,0.17),R20.2],and thiswasalso found ina subgroup
analysis of HNF1A mutation carriers [P  0.004,   0.53
(0.86, 0.20), R2 0.48], whereas there was no association
between pancreatic volume index and current age or BMI. Pan-
creatic volume index was associated with fecal elastase defi-
ciency in subjectswith diabetes of any type [P 0.03;6.86
(13.0,  0.72), R2 0.09]; however, no such association was
observedwithinanydiabetessubgroup.Inthemultivariateanalysis,
pancreatic volume index was significantly higher in HNF1A mu-
tation carriers than in type 1 diabetes subjects after adjusting for
age, diabetes duration, and fecal elastase deficiency [P  0.001,
11.86 (16.91, 6.81), R2 0.49].
Pancreatic x-ray attenuation
The global assessment by ANOVA showed significant variance
for the mean pancreatic x-ray attenuation (P  0.007; F 4.37,
3 df). The mean pancreatic x-ray attenuation in HNF1A mutation
carriers (81.1 19.4 HU) was not statistically different from non-
diabetic controls (66.0  23.6 HU, P  0.09; Fig. 1, B and C).
Interestingly, the attenuation was significantly increased in type 1
diabetes patients (84.4  21.9 HU), compared with nondiabetic
controls (P  0.02), whereas subjects with type 2 diabetes had
attenuationsimilar tonondiabetic controls (60.121.4HU).Fecal
elastase deficiency was not associated with pancreatic attenuation.
Pancreatic attenuation was significantly and inversely associated
with age [P0.04,0.50 (0.97, 0.03), R20.06] andBMI
[P  0.001,   3.27 (5.20,  1.19), R2  0.20] in the uni-
FIG. 1. Pancreatic volume and x-ray attenuation. Helical CT was performed as described in Subjects and Methods. The pancreatic volume index was calculated by
dividing pancreatic volume by body surface area to control for the influence of body build on pancreatic volume. *, Statistical difference (P  0.05). A, Pancreatic
volume index was reduced in HNF1A mutation carriers, compared with nondiabetic controls (P  0.02), whereas type 1 diabetes (T1D) subjects had reduced pancreatic
volume index compared with HNF1A mutation carriers, type 2 diabetes (T2D) patients, and nondiabetic controls (all P  0.001). B, For HNF1A mutation carriers, the
mean pancreatic attenuation did not differ from nondiabetic controls or type 1 diabetes patients. The mean pancreatic attenuation was increased in type 1 diabetes
patients, compared with nondiabetic controls (P  0.04). C, CT at the level of the pancreatic body and tail in an HNF1A mutation carrier, a patient with type 1 diabetes
and fecal elastase deficiency, and a nondiabetic control. The pancreas of the type 1 diabetes subject demonstrates reduced volume and increased attenuation. No
striking differences are apparent between the HNF1A mutation carrier and the control subjects. When analyzed at the group level, HNF1A mutation carriers have
significantly smaller pancreatic volume and a trend toward higher mean x-ray attenuation than nondiabetic subjects. The arrows mark the position of the pancreas.
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variate linear regression analyses. Adjusting for age and BMI in a
multivariate regression analysis only slightly modified the asso-
ciation of pancreatic attenuationwith diabetes status in the com-
parison of nondiabetic controls and HNF1A mutation carriers
[P  0.11,   12.99 (2.94, 28.93), R2  0.41] or type 1
diabetes [P  0.009,   18.42 (4.84, 31.99), R2  0.45],
respectively.
Discussion
To our knowledge, this is the first study on pancreatic size and
structure in HNF1A-MODY. We found that HNF1A as well as
type 1 diabetes patients had significantly reduced pancreatic vol-
ume index, compared with nondiabetic controls. Our results for
types 1 and2diabetes are consistentwith previous reports (6, 15,
16). Subjects with type 1 diabetes had smaller pancreatic volume
index than HNF1A mutation carriers, and this reduction re-
mained significant after adjusting for age, diabetes duration, and
fecal elastase deficiency. Reduced pancreatic volume index was
associatedwithdiabetes duration in agreementwith some (8) but
not all (6, 7) previous studies. Reduced insulinotropic effects on
the acinar cells is a possible mechanism for the reduction in pan-
creatic volume (10, 11), and reports show association of small
pancreatic volume with insulin use (8) or reduced insulin secre-
tion (7). This is in line with our data because type 1 diabetes
patients generally have the most pronounced endogenous
insulinopenia.
Subjects with fecal elastase deficiency had a significant re-
duction in pancreatic volume index, in accordance with a recent
report showing an association between pancreatic volume index
and the exocrine pancreatic function marker serum immunore-
active trypsin (6). Both the reduced pancreatic volume and re-
duced pancreatic exocrine function observed in our patientsmay
be due to local paracrine effects of insulinopenia (10). The more
severe insulin deficiency observed in type 1 diabetes probably
explains the greater pancreatic volume reduction comparedwith
HNF1A-MODY. We cannot, however, rule out the possibility
that primary exocrine disease is involved in the pancreatic vol-
ume reduction.
A recent study reported higher pancreatic fat content in type
2 diabetic compared with nondiabetic men and a negative cor-
relation of pancreatic fat with -cell function (17), whereas oth-
ers found no increase in pancreatic fat in type 2 diabetes (16).
Interestingly, we experienced that pancreatic x-ray attenuation
adjusted for age and BMI was significantly increased in subjects
with type 1 diabetes and observed the same tendency in HNF1A
mutation carriers. In contrast, type 2 diabetes patients had pan-
creatic x-ray attenuation similar to controls. We further found
that pancreatic x-ray attenuation decreased with increasing
BMI, confirmingprevious findingsof strongcorrelationbetween
BMI and fat content in the pancreas (16, 18). The observed dif-
ferences between diabetes subtypes may be due to differences in
insulin secretion, which has been reported to be directly associ-
ated with pancreatic fat content (18).
Pancreatic lipomatosis is an early structural marker of pan-
creatic exocrine disease in CEL mutation carriers preceding
development of diabetes (5). Fatty replacement of the pan-
creas has also been observed in cystic fibrosis and Johansson-
Blizzard syndrome, two monogenic conditions with primary
affection of the exocrine pancreas and frequent development
of secondary diabetes (19, 20). We did not find any associa-
tion of pancreatic x-ray attenuation with fecal elastase in
HNF1A mutation carriers. This suggests a different patho-
physiological mechanism for the development of pancreatic
changes in HNF1A-MODY.
In conclusion, the pancreatic volume index was reduced in
HNF1A-MODY, compared with nondiabetic controls, but less
than in type 1 diabetes. A striking pancreatic atrophy such as in
HNF1B MODY was not observed. Although HNF1A and
HNF1B are closely related and interact in the same transcrip-
tional network, HNF1A clearly has less pronounced effect on
pancreas volume and structure than HNF1B (1, 2, 21). Our data
support the notion that insulinopenia is the main factor deter-
mining the reduction inpancreatic volume inHNF1A-MODYas
well as in type 1 diabetes, whereas in HNF1B-MODY a devel-
opmental effect is likely to be involved. Insulinopenia probably
also explains the pancreatic exocrine dysfunction associated
with pancreatic volume reduction, but further studies, par-
ticularly of nondiabetic HNF1A mutation carriers, would be
helpful to evaluate a possible primary role of the exocrine
pancreas.
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